Foundation Medicine Reports Identified Patients Likely to Respond to Certain MET Inhibitor Target Therapies, Durable Responses Shown in Presentation at ASCO

By: via Benzinga
Foundation Medicine, Inc. (NASDAQ: FMI) today announced new data demonstrating the role of MET exon 14 (METex14) alterations as drivers ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.